ArticlePloS one2025
Global, regional and national retinoblastoma burden in children under 10 years of age from 1990 to 2021: Trend analysis based on the Global Burden of Disease Study 2021.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Noncoding RNAs in Pediatric Solid Tumors: Advances in Understanding and Critical Knowledge Gaps.Cells · 2026Review
- Histopathological spectrum of ocular masses in a tertiary eye center in Northern China: a 12-year retrospective analysis.Frontiers in medicine · 2026Article
- Development and validation of transient receptor potential channel-related signature for predicting prognosis in patients with lung adenocarcinoma.Oncology letters · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRetinoblastoma (RB) is the most common malignant eye tumor in children, which poses a great threat to children's vision and life. Comprehensive global, regional and country-level assessments of retinoblastoma in children under 10 years of age are important to help fine-tune health policies and rationalize the allocation of medical resources.
methodsData on RB-related burden in children under 10 years of age were collected in the 2021 Global Burden of Disease (GBD) study to assess trends in RB burden using mean annual percentage change (AAPC). Absolute and relative health inequalities of RB burden were analyzed using slope index and concentration index. An age-period-cohort model was fitted using package NORDPRED to predict the future RB burden.
resultsThe global number of RB cases in children under 10 years of age in 2021 was 57,333 (95%UI: 34339.65,761.03), the annual standardized prevalence rate (ASPR) was 4.39(95%UI: 2.63, 5.95), and the AAPC (1990-2021) was 0.65(95%CI: 0.44, 0.86). Over the past 30 years, age-standardised mortality (ASMR) and age-standardised DALY(ASDR) have declined globally. At the level of socio-demographic index (SDI) regions, ASIR and ASPR were the highest in the medium-high SDI and high SDI regions, with ASPR being 6.03(95%UI: 3.01-9.21) and 5.44(95%UI: 3.97-7.18), and ASIR being 0.66(95%UI: 0.33-1.01) and 0.59(95%UI: 0.43-0.78). The mortality and DALYs of RB decreased gradually with the increase of SDI. At the country level, China and India are the countries with the highest number of cases, together accounting for about 30% of the global cases, and ASIR is still on the rise in these two countries. The inequality analysis shows that RB burden is heavier in countries with lower SDI. The number of RB cases worldwide is expected to rise slowly, but the global burden will gradually decrease.
conclusionAs one of the main causes affecting the life and health of children, with the increase in the number of diseases worldwide, it is necessary for decision-makers to customize relevant intervention policies to provide effective prevention and control measures to help achieve the global Sustainable Development Goals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.